S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
S&P 500   4,195.94 (-0.23%)
DOW   32,940.03 (-0.46%)
QQQ   349.01 (+0.18%)
AAPL   177.04 (+0.92%)
MSFT   331.01 (-0.56%)
META   262.03 (+0.00%)
GOOGL   122.66 (-1.56%)
AMZN   121.06 (+0.79%)
TSLA   197.88 (+2.44%)
NVDA   400.10 (+2.73%)
NIO   7.40 (-3.90%)
BABA   78.31 (-3.29%)
AMD   125.44 (-1.25%)
T   15.60 (+0.65%)
F   12.62 (+4.38%)
MU   71.94 (-2.69%)
CGC   0.86 (-1.97%)
GE   101.89 (-0.83%)
DIS   87.16 (-1.28%)
AMC   4.58 (-1.29%)
PFE   37.06 (-1.44%)
PYPL   61.40 (+1.96%)
NFLX   388.73 (+2.60%)
NASDAQ:SNGX

Soligenix (SNGX) Stock Forecast, Price & News

$0.71
-0.02 (-2.07%)
(As of 01:58 PM ET)
Compare
Today's Range
$0.70
$0.72
50-Day Range
$0.71
$2.29
52-Week Range
$0.65
$15.00
Volume
149,418 shs
Average Volume
551,475 shs
Market Capitalization
$2.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Soligenix MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
4.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Soligenix in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.55) to ($3.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.12 out of 5 stars


SNGX stock logo

About Soligenix (NASDAQ:SNGX) Stock

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Why Are Soligenix Shares Trading Higher Today
Soligenix Provides Regulatory Update on HyBryte™
Why Is Soligenix (SNGX) Stock Down 27% Today?
Why Is Soligenix (SNGX) Stock Down 35% Today?
Soligenix Announces Reverse Stock Split
See More Headlines
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Company Calendar

Last Earnings
11/12/2021
Today
5/30/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNGX
Employees
13
Year Founded
1987

Profitability

Net Income
$-13,800,000.00
Net Margins
-996.96%
Pretax Margin
-1,218.01%

Debt

Sales & Book Value

Annual Sales
$950,000.00
Book Value
($0.85) per share

Miscellaneous

Free Float
2,857,000
Market Cap
$2.16 million
Optionable
Not Optionable
Beta
1.74

Social Links


Key Executives

  • Christopher J. SchaberChristopher J. Schaber
    Chairman, President & Chief Executive Officer
  • Jonathan L. GuarinoJonathan L. Guarino
    Chief Financial Officer, Secretary & Senior VP
  • Oreola Donini
    Chief Scientific Officer & Senior Vice President
  • Richard C. Straube
    Chief Medical Officer & Senior Vice President
  • Adam T. Rumage
    VP-Regulatory Affairs & Project Management













SNGX Stock - Frequently Asked Questions

How have SNGX shares performed in 2023?

Soligenix's stock was trading at $0.4520 at the start of the year. Since then, SNGX stock has increased by 60.4% and is now trading at $0.7250.
View the best growth stocks for 2023 here
.

Are investors shorting Soligenix?

Soligenix saw a increase in short interest in May. As of May 15th, there was short interest totaling 350,100 shares, an increase of 63.0% from the April 30th total of 214,800 shares. Based on an average daily trading volume, of 835,000 shares, the short-interest ratio is presently 0.4 days. Approximately 4.4% of the shares of the stock are sold short.
View Soligenix's Short Interest
.

When is Soligenix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our SNGX earnings forecast
.

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.80 million. Soligenix had a negative net margin of 996.96% and a negative trailing twelve-month return on equity of 589.84%.

What other stocks do shareholders of Soligenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soligenix investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Trevena (TRVN), Vaxart (VXRT), OPKO Health (OPK), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Actinium Pharmaceuticals (ATNM).

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

Who are Soligenix's major shareholders?

Soligenix's stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Wilshire Securities Management Inc. (0.78%) and Geode Capital Management LLC (0.73%). Insiders that own company stock include Christopher J Schaber, Jerome B Zeldis, Jonathan L Guarino and Richard Straube.
View institutional ownership trends
.

How do I buy shares of Soligenix?

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soligenix's stock price today?

One share of SNGX stock can currently be purchased for approximately $0.73.

How much money does Soligenix make?

Soligenix (NASDAQ:SNGX) has a market capitalization of $2.16 million and generates $950,000.00 in revenue each year.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The official website for the company is www.soligenix.com. The biopharmaceutical company can be reached via phone at (609) 538-8200, via email at ir@soligenix.com, or via fax at 609-452-6467.

This page (NASDAQ:SNGX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -